We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Emission Solutions (EMSOL) empowers organisations to take everyday steps to reduce emissions through their real-time emission monitoring and analytics system. EMSOL's open framework platform is built with networks of sensors like air and noise pollution, vehicle tracking, and working with any asset tags and emission sensors which enables EMSOL to perform real-time measurements with location tags and calibrated sensors. Data from these platforms are easily shared on dashboards, through notifications and gives detailed real-time data on urban noise, air quality, and vehicle pollution. To date, EMSOL won Rushlight Environmental Analysis Award, achieve yearly income targets, rated 5th place in the national PowerUp Index and 4th in the London and South East region. Moreover, EMSOL also won a fully funded project sponsored by DFT to deploy EMSOL technology into the rail sector. The company will use the funds to expand its customer base and increase the number of deployment sites.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £316,884
Innovate Recycle (IR) is a company that aims to reduce carbon emissions from burning discarded carpets. It asserts that only 2% of the 400,000 tonnes of discarded carpets in the UK is recycled, with the rest going into a landfill or being incinerated. IR further points out that burning waste carpet leads to an estimated CO2 impact of £16 million per annum in the UK. It wants to solve this crisis. IR is building a new carpet recycling plant in Northamptonshire that would be able to recycle carpets into reusable materials. They have already received grant funding of up to £2.35 million. IR claims that a single production line in the plant, at full capacity, can recycle up to 20,000 tonnes each year and generate 12,600 tonnes of polypropylene pellets. It will use the investment to expand to a second production line by Year 4 at the same facility.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £2,650,000
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £326,190
Orbital Marine Power aims to harness the energy flowing in tidal streams and rivers through its award-winning tidal turbines. Orbital's O2 turbine is designed to deliver enough power for up to 2,000 homes. The company's vision is to focus on providing turbines and services into a future £20 billion per annum utility-scale global market for clean and predictable power from tidal streams. Orbital is currently providing £15 million of funded design projects to refine its IP protected low carbon tidal technology in readiness to scale up and play its part in meeting the ever-increasing demand for clean power. It will use the investment to grow its business across different verticals.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £2,595,231
Toraphene is an environmental technology company that aims to eliminate plastic waste. It has released with its product, Toraphene, to solve this crisis. It claims that Toraphene is a biodegradable, compostable and commercially-viable plastic packaging substitute for conventional plastic. The company asserts that its product is biodegradable even in the ocean, and has been developed using graphene technology. It is focussed on eliminating carrier bags and food containers in its first-round which account for 23% of marine waste. It aims to be a segment leader in the projected $25.4 billion biodegradable plastic industry by 2026. The company will use the investment to make Toraphene accessible to companies worldwide and make plastic packaging obsolete.

Pitch Rated

80%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £1,000,000
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,036,436
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £134,892
Square Mile Farms (SMF) is a company that installs innovative and productive vertical farms in a workplace to engage employees and help businesses create a culture of healthy, low-impact living. Its 'Office Farming' model creates green spaces for engagement and collaboration. In 2019, it was invited to build a vertical farm in Paddington Central by British Land, one of UK’s largest landowners. The setup now acts as a hub for the company's office farm installations and a base from which it can conduct Research and Development (R&D). SMF's customers include Grosvenor Group Limited and Vodafone. Moreover, the company has been covered by media platforms such as BBC One and BBC Radio. It will use 45% of the investment for sales and business development, 15% for design and technology up-gradation, 15% for raising its profile and increasing brand awareness, and 25% for operations.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £504,118
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £532,311
Creative Hub is a fast-growing cloud software platform for creative people to store, share files, and collaborate on projects. The collaboration tools also allow users to chat in real-time, and add comments on images, allowing creative teams to work faster and deliver better results. Creative Hub enables users to order professional art & photographic prints, or physical 3D prints, which are produced at its print production facilities in London(UK) and Dusseldorf (Germany). The platform currently has 40,000 active users which are growing day by day. With the investment, the company will drive growth through marketing and launch its New York production facility.

Pitch Rated

76%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £286,992
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph